A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

NCT05127486 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

580

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine
Episodic Migraine

Interventions

DRUG: Galcanezumab
DRUG: Rimegepant
DRUG: Placebo
DRUG: Placebo

Sponsor

Eli Lilly and Company